Table I.
KEGG pathways significantly enriched for differentially expressed genes during F. tularensis infection
| Time Point | Pathway | Hits | P-value |
|---|---|---|---|
| 3 hr | Glycolysis/Gluconcogcncsis | 6 | 1.92E-04 |
| 3 hr | *MAPK signaling pathway | 9 | 0.0027 |
| 3 hr | Prion diseases | 4 | 0.0040 |
| 3 hr | Graft-versus-host disease | 4 | 0.0044 |
| 3 hr | Hematopoietic cell lineage | 5 | 0.0074 |
| 3 hr | Cytokine-cytokine receptor interaction | 8 | 0.0085 |
| 3 hr | *NOD-like receptor signaling pathway | 4 | 0.0195 |
| 3 hr | *Apuptosis | 4 | 0.0465 |
| 6 hr | Glycolysis/Gluconeogenesis | 14 | 2.23E-06 |
| 6 hr | Fructose and mannosc metabolism | 9 | 1.14E-04 |
| 6 hr | *NOD-like receptor signaling pathway | 11 | 4.57E-04 |
| 6 hr | Pentose phosphate pathway | 7 | 7.54E-04 |
| 6 hr | *Neurotrophin signaling pathway | 15 | 0.0015 |
| 6 hr | *Apuptosis | 12 | 0.0020 |
| 6 hr | *MAPK signaling pathway | 24 | 0.0025 |
| 6 hr | T cell receptor signaling pathway | 13 | 0.0037 |
| 6 hr | *Chronic myeloid leukemia | 10 | 0.0070 |
| 6 hr | *Pancreatic cancer | 9 | 0.0168 |
| 6 hr | *Toil-like receptor signaling pathway | 11 | 0.0171 |
| 6 hr | Mismatch repair | 5 | 0.0194 |
| 12 hr | Pentose phosphate pathway | 12 | 1.09E-06 |
| 12 hr | Glycolysis/Gluconeogenesis | 16 | 4.53E-05 |
| 12 hr | *Apoptosis | 18 | 3.80E-04 |
| 12 hr | Fructose and mannose metabolism | 10 | 9.89E-04 |
| 12 hr | *NOD-like receptor signaling pathway | 13 | 0.0029 |
| 12 hr | *Neurotrophin signaling pathway | 20 | 0.0037 |
| 12 hr | *Pancreatic cancer | 14 | 0.0038 |
| 12 hr | *Chronic myeloid leukemia | 14 | 0.0054 |
| 12 hr | Galactose metabolism | 7 | 0.0140 |
| 12 hr | Adipocytokine signaling pathway | 12 | 0.0152 |
| 12 hr | Starch and sucrose metabolism | 9 | 0.0156 |
| 12 hr | Chondroitin sulfate biosynthesis | 6 | 0.0260 |
| 12 hr | *Insulin signaling pathway | 18 | 0.0368 |
| 12 hr | *Prostate cancer | 13 | 0.0468 |
| 24 hr | Lysosome | 36 | 8.35E-05 |
| 24 hr | Pentose phosphate pathway | 13 | 1.64E-04 |
| 24 hr | B cell receptor signaling pathway | 25 | 3.58E-04 |
| 24 hr | *Acute myeloid leukemia | 20 | 0.0010 |
| 24 hr | Glycolysis/Gluconeogenesis | 20 | 0.0017 |
| 24 hr | *Neurotrophin signaling pathway | 33 | 0.0027 |
| 24 hr | *NOD-like receptor signaling pathway | 19 | 0.0061 |
| 24 hr | *Pancreatic cancer | 21 | 0.0069 |
| 24 hr | *Apoptosis | 23 | 0.0150 |
| 24 hr | Amino sugar and nucleotide sugar metabolism | 14 | 0.0160 |
| 24 hr | T cell receptor signaling pathway | 27 | 0.0165 |
| 24 hr | *p53 signaling pathway | 19 | 0.0167 |
| 24 hr | *Chronic myeloid leukemia | 20 | 0.0224 |
| 24 hr | Ubiquitin mediated proteolysis | 32 | 0.0224 |
Genes that were significantly differentially expressed in control and LVS-infected neutrophils were used for pathway analysis. The KEGG pathways identified by DAVID to be significantly modulated by LVS are listed. Hits indicate the number of genes in our data set identified in the each particular KEGG pathway. Asterisks indicate pathways linked to apoptosis or cell survival.